Searching for just a few words should be enough to get started. If you need to make more complex queries, use the tips below to guide you.
Article type: Review Article
Authors: Yang, Jianweia | Jia, Longfeia; b; c; d | Li, Yana | Qiu, Qiongqionga | Quan, Meinaa | Jia, Jianpinga; b; c; d; *
Affiliations: [a] Innovation Center for Neurological Disorders and Department of Neurology, Xuanwu Hospital, Capital Medical University, National Clinical Research Center for Geriatric Diseases, Beijing, People’s Republic of China | [b] National Clinical Research Center for Geriatric Diseases, Beijing, People’s Republic of China | [c] Clinical Center for Neurodegenerative Disease and Memory Impairment, Capital Medical University, Beijing, People’s Republic of China | [d] Center of Alzheimer’s Disease, Beijing Institute for Brain Disorders, Beijing, People’s Republic of China
Correspondence: [*] Correspondence to: Jianping Jia, MD, PhD, Innovation Center for Neurological Disorders, Department of Neurology, Xuanwu Hospital, Capital Medical University, 45 Changchun Street, Beijing, China. Tel.: +86 10 83199449; Fax: +86 10 83171070; E-mail: E-mail: jiajp@vip.126.com.
Abstract: Alzheimer’s disease (AD) research is entering a unique moment in which enormous information about the molecular basis of this disease is being translated into therapeutics. However, almost all drug candidates have failed in clinical trials over the past 30 years. These many trial failures have highlighted a need for the incorporation of biomarkers in clinical trials to help improve the trial design. Fluid biomarkers measured in cerebrospinal fluid and circulating blood, which can reflect the pathophysiological process in the brain, are becoming increasingly important in AD clinical trials. In this review, we first succinctly outline a panel of fluid biomarkers for neuropathological changes in AD. Then, we provide a comprehensive overview of current and future application of fluid biomarkers in clinical trials for AD. We also summarize the many challenges that have been encountered in efforts to integrate fluid biomarkers in clinical trials, and the barriers that have begun to be overcome. Ongoing research efforts in the field of fluid biomarkers will be critical to make significant progress in ultimately unveiling disease-modifying therapies in AD.
Keywords: Alzheimer’s disease, biomarkers, blood biomarkers, cerebrospinal fluid, clinical trials
DOI: 10.3233/JAD-201068
Journal: Journal of Alzheimer's Disease, vol. 81, no. 1, pp. 19-32, 2021
IOS Press, Inc.
6751 Tepper Drive
Clifton, VA 20124
USA
Tel: +1 703 830 6300
Fax: +1 703 830 2300
sales@iospress.com
For editorial issues, like the status of your submitted paper or proposals, write to editorial@iospress.nl
IOS Press
Nieuwe Hemweg 6B
1013 BG Amsterdam
The Netherlands
Tel: +31 20 688 3355
Fax: +31 20 687 0091
info@iospress.nl
For editorial issues, permissions, book requests, submissions and proceedings, contact the Amsterdam office info@iospress.nl
Inspirees International (China Office)
Ciyunsi Beili 207(CapitaLand), Bld 1, 7-901
100025, Beijing
China
Free service line: 400 661 8717
Fax: +86 10 8446 7947
china@iospress.cn
For editorial issues, like the status of your submitted paper or proposals, write to editorial@iospress.nl
如果您在出版方面需要帮助或有任何建, 件至: editorial@iospress.nl